Publications by authors named "Rashmi Murthy"

Claim this Profile
R
Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer.
Inimfon Jackson, Xiudong Lei, Hui Zhao, Rashmi Murthy, Sharon H Giordano

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generalizable morphological profiling of cells by interpretable unsupervised learning.
Rashmi Sreeramachandra Murthy, Shobana V Stassen, Dickson M D Siu, Michelle C K Lo, Gwinky G K Yip

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study.
Maria Azhar, Felipe Soto, Amber Su, Norma Alicia Vazquez Gonzalez, Kevin Bernal Medina, Rashmi K Murthy

Breast Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chylothorax in Uncommon Contexts: Pulmonary Tuberculosis and Mantle Cell Lymphoma.
Guru Prasad T J, Athish Kannan Karur, Spurthy Padmanabha, K R Harshitha, Suggula Vamsi Krishna, Rashmi Priya Murthy

Respirol Case Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon, Rashmi Murthy

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sleep disturbances based on patient reported outcomes in patients with breast cancer.
Saadia A Faiz, Ashley S Knox, Bryan Fellman, Bibi Aneesah Jaumally, G Nancy Pacheco, Rashmi Murthy

Sleep Breath· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype.
Grace L Smith, Benjamin D Smith, Chi-Fang Wu, Simona F Shaitelman, Mariana Chavez-MacGregor, Rashmi Murthy

Breast· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.
Clinton Yam, Miral Patel, Holly A Hill, Ryan Sun, Roland L Bassett, Rashmi K Murthy

Cancer Res Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, Denái R Milton, Angelica M Gutierrez, Rashmi K Murthy

Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Rashmi K Murthy

Ther Adv Med Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Mark Pegram, Richard Pietras, Chau T Dang, Rashmi Murthy, Thomas Bachelot

Ther Adv Med Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Clinton Yam, Elizabeth A Mittendorf, Haven R Garber, Ryan Sun, Senthil Damodaran, Rashmi K Murthy

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.
Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M Rauch, Qingqing Ding, Rashmi K Murthy

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot

JAMA Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E D Van Swearingen, Rashmi K Murthy

Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi, Rashmi K Murthy

Cancer Discov· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, Rashmi Murthy

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E Adrada, Qing-Qing Ding, Rashmi K Murthy

Clin Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.
Nour Abuhadra, Ryan Sun, Jennifer K Litton, Gaiane M Rauch, Clinton Yam, Rashmi K Murthy

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to A. Pfob and C. Sidey-Gibbons.
Carlos H Barcenas, Juhee Song, Rashmi K Murthy, Akshara S Raghavendra, Yisheng Li

JCO Clin Cancer Inform· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
Shannon N Westin, Marilyne Labrie, Jennifer K Litton, Aurora Blucher, Yong Fang, Rashmi Murthy

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
W Fraser Symmans, Christina Yau, Yunn-Yi Chen, Ron Balassanian, Molly E Klein, Rashmi K Murthy

JAMA Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer.
Carlos H Barcenas, Juhee Song, Rashmi K Murthy, Akshara S Raghavendra, Yisheng Li

JCO Clin Cancer Inform· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036.
Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, Samantha M Bevill, Daniel R Goulet, Rashmi Murthy

NPJ Breast Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
R Connor Chick, G Travis Clifton, Diane F Hale, Timothy J Vreeland, Annelies T Hickerson, Rashmi K Murthy

Clin Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis